Skip to content

The Significance of Sodium Balance and the Value of Salt-blood Test in Identifying Salt Sensitive Patients

The Significance of Sodium Balance for Blood Pressure in Patients With Essential Hypertension and the Value of Salt-blood Test in Identifying Salt Sensitive Patients With Hypertension

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05165823
Acronym
VASA
Enrollment
72
Registered
2021-12-21
Start date
2022-02-08
Completion date
2023-07-26
Last updated
2023-09-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension,Essential

Keywords

Salt sensitivity, Sodium sensitivity, Salt restriction, Salt-blood test, Dietary intervention, Hypertension

Brief summary

This is a randomized controlled trial with 72 patients with hypertension examining the effects on blood pressure of sodium restriction and whether the blood analysis Salt-blood test is associated to a decrease in blood pressure. Patients will be randomized 2:1 to either sodium restriction or usual diet for 4 weeks. Baseline measures will be done before intervention and outcome measures after the 4 weeks.

Interventions

Participants will be guided in minimizing sodium intake. Guidance will be both oral and written. Bread with low sodium content will be offered to the participants.

Sponsors

Regional Hospital Holstebro
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* BMI ≤ 35 kg/m2 * Essential hypertension * eGFR \> 15 ml/min/1,73m2 * Albumine-to-creatinine-ratio \< 500 mg/g * Safe anticonception if women in childbearing age. * Able to adhere to dietary regimen

Exclusion criteria

* Secondary hypertension * Clinically significant heart failure (NYHA 3-4) * Clinically significant liver disease * Diabetes mellitus (type 1 and 2) * Active cancer (except skin cancer) * Renal transplant * Recent stroke, transcient ischemic attack or myocardial infarction (within 6 months) * Proliferative glomerulonephritis or ANCA-related disease * Continuous immunosuppressant treatment * Pregnancy or lactation * Alcohol abuse * If the investigator finds the participant unfit to complete the project

Design outcomes

Primary

MeasureTime frameDescription
Change in systolic 24-hour blood pressureMeasured before and after 4 weeks' interventionDifference in systolic blood pressure measured before and after intervention

Countries

Denmark

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 6, 2026